Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis

Residual Vein Thrombosis (RVT) to Assess Optimal Management of DVT: DACUS Study⁶

June 2011

Another tool that can be used for risk stratification is the presence or absence of residual vein thrombosis assessed by ultrasound and this is the study that was assessed in the DACUS trial. These investigators took 250 patients, treated them with warfarin for at least 3 months and then assessed residual thrombus by ultrasound. If there was residual thrombus, then they randomized patients either to resume warfarin or to stop warfarin; if there was no residual thrombus then they simply stopped warfarin therapy.

< Previous Slide

RVT to Assess Optimal Management of DVT6

Next Slide >

 

Jump to section:

• Introduction
• Independent Risk Factors for Venous Thromboembolism¹
• Thrombophilia Testing
• ACCP Treatment Duration Guidelines²
• Aggressive Thrombophilia²
• Case
• Case
• Recurrence Rate
• ACCP Treatment Duration Guidelines³
• D-Dimer Levels and Risk of Recurrent Venous Thromboembolism⁴
• PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation⁵
• PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation⁵
• Idiopathic VTE
• Residual Vein Thrombosis (RVT) to Assess Optimal Management of DVT: DACUS Study⁶
• Residual Vein Thrombosis (RVT) to Determine Duration of Anticoagulation⁶
• Recurrent VTE by RVT at 3 Months: DACUS Study⁶
• Non-compressed vs. Compressed
• Idiopathic DVT: Take Home Point
• Case (revisited)
• Case (revisited)
• Mortality Risk
• Cumulative Recurrence of DVT vs PE After Incident DVT
• Cumulative Recurrence of DVT vs PE After Incident PE
• Independent Predictors of Death within 7 Days of Venous Thromboembolism Recurrence
• Idiopathic PE – Take Home Points
• References
• Clinical and Laboratory Update in Thrombosis and Anticoagulation
• Questions?